The case for & against
Bull & Bear analysis
Bearish
XOMA Royalty Corp (XOMAO) is a specialized provider of royalty rights to pharmaceutical and biotechnology companies. Following its acquisition by Ligand Pharmaceuticals, the company has transitioned from being an independent entity to a wholly owned subsidiary, shifting its investor dynamics and focus. Its primary theme centers around the management of healthcare royalties and potential litigation payouts, which has implications for investors holding preferred shares.
Bull says
- ↑8.375% dividend yield with mandatory $25 redemption on July 14, 2026
- ↑CVRs offer contingent rights to litigation proceeds, enhancing potential returns
- ↑Backed by Ligand infrastructure, may improve royalty income management
- ↑Q1 2026 EPS miss offset by committed cash dividends
- ↑Hedge fund interest and potential buybacks may support price momentum
- ↑Attractive hold given yield vs sector alternatives despite earnings weakness
Bear says
- ↓Q1 2026 EPS of -$0.03 missed consensus by 117%, undercutting earnings
- ↓Delisting from Nasdaq undermines independent visibility and investor trust
- ↓Dividend sustainability risks heightened by reliance on acquisition payouts
- ↓July 14, 2026 mandatory redemption caps upside and squeezes liquidity
- ↓Negative post-earnings market reaction reflects skepticism and high volatility
- ↓Uncertain royalty income and litigation outcomes threaten cash flow